Oncimmune a biomarker discovery company focused on the profiling of autoantibodies and discovery of novel immune biomarker signatures, announces that they will participate at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in-person on June 2-6, 2023, in Chicago, Illinois. The company will be exhibiting at booth 18156.
Data highlighting ImmunoINSIGHTS™ novel technology will also be presented to demonstrate the utility autoantibody profiling in non small cell lung cancer (NSCL) in treatment with checkpoint inhibitors (ICI) in pre-existing autoimmune diseases patients.
Title: Baseline autoantibody profiling in NSCLC patients with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study
Abstract # 2512
Session Type: Rapid Abstract Session
Session Title: Developmental Therapeutics – Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Sub Track: Circulating Biomarkers
Session Date and Time: Friday June 2, 2023, 4-5pm
Presenters : Delvys Rodriguez-Abreu
For more information, visit the ASCO Annual Meeting website.